Given the improved CNS efficacy of third generation osimertinib, the results of the phase II OUTRUN (NCT03497767) comparing osimertinib versus osimertinib with SRS in patients with EGFR-mutated NSCLC with the primary endpoint of intracranial PFS are eagerly awaited. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.